Skip to main content
SpringerLink
Log in

Epithelial ovarian cancer

  • Published:
Current Treatment Options in Oncology Aims and scope Submit manuscript

Opinion statement

Epithelial ovarian cancer is the most lethal of all gynecologic malignancies. Most women have advanced stage disease. Access to appropriate initial surgical management by a gynecologic oncologist is important because treatment and survival are affected by appropriate surgical staging and debulking of tumor. After debulking/ staging surgery, chemotherapy with platinum-taxane-based regimens is appropriate for most patients. Patients with early stage, low-risk tumors may be cured with surgery alone. Interval cytoreductive surgery may be appropriate for patients who are initially suboptimally cytoreduced and are stable or responding to chemotherapy. The role of second-look surgery remains to be defined. Patients with recurrent or relapsed ovarian cancer are incurable. There are several chemotherapy agents that can achieve disease responses, which may be associated with palliation of tumor-related symptoms. Participation in clinical trials is encouraged for all patients. Novel approaches to managing minimal residual disease are being tested in hopes of decreasing the number of patients who relapse after achieving complete clinical remission.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References and Recommended Reading

  1. Landis SH, Murray T, Bolden S, Wingo PA: Cancer statistics, 1999. CA Cancer J Clin 1999, 49:8–31.

    Article  PubMed  CAS  Google Scholar 

  2. Young RC, Walton LA, Ellenberg SS, et al.: Adjuvant therapy in stage I and II epithelial ovarian cancer. Results of two prospective randomized trials. N Engl J Med 1990, 322:1021–1027.

    Article  PubMed  CAS  Google Scholar 

  3. Hoskins WJ, McGuire WP, Brady MF, et al.: The effect of diameter of largest residual disease on survival after primary cytoreductive surgery in patients with suboptimal residual epithelial ovarian carcinoma. Am J Obstet Gynecol 1994, 170:974–979.

    PubMed  CAS  Google Scholar 

  4. Bonnefoi H, A'Hern RP, Fisher C, et al.: Natural history of stage IV epithelial ovarian cancer. J Clin Oncol 1999, 17:767–775.

    PubMed  CAS  Google Scholar 

  5. McGuire WP, Hoskins WJ, Brady MF, et al.: Cyclophosphamide and cisplatin compared with paclitaxel and cisplatin in patients with stage III and stage IV ovarian cancer. N Engl J Med 1996, 334:1–6.

    Article  PubMed  CAS  Google Scholar 

  6. Ford D, Easton DF, Bishop DT, et al.: Risk of cancer in BRCA1-mutation carriers. Lancet 1994, 343:692–695.

    Article  PubMed  CAS  Google Scholar 

  7. Burke W, Daly M, Garber J, et al.: Recommendations for follow-up and care of individuals with inherited predisposition to cancer, II: BRCA1 and BRCA2. Cancer Genetics Studies Consortium. JAMA 1997, 277:997–1003.

    Article  PubMed  CAS  Google Scholar 

  8. Ozols RF, Morgan RJ, Copeland L, et al.: Update of the NCCN ovarian cancer practice guidelines. Oncology 1997, 11:95–105.

    PubMed  CAS  Google Scholar 

  9. McGowan L, Lesher LP, Norris HJ, Barnett M: Mis-staging of ovarian cancer. Obstet Gynecol 1985, 65:568–572.

    PubMed  CAS  Google Scholar 

  10. van der Burg MEL, van Lent M, Buyse M, et al.: The effect of debulking surgery after induction chemotherapy on the prognosis in advanced epithelial ovarian cancer. N Engl J Med 1995, 332:629–634.

    Article  PubMed  Google Scholar 

  11. Barakat RR, Almadrones L, Venkatraman ES, et al.: A Phase II trial of intraperitoneal cisplatin and etoposide as consolidation therapy in patients with stage IIIV epithelial ovarian cancer following negative surgical assessment. Gynecol Oncol 1998, 69:17–22.

    Article  PubMed  CAS  Google Scholar 

  12. Young RC, Walton LA, Ellenberg SS, et al.: Adjuvant therapy in stage I and stage II epithelial ovarian cancer. Results of two prospective randomized trials. N Engl J Med 1990, 322:1021–1027.

    Article  PubMed  CAS  Google Scholar 

  13. Pecorelli S, Bolis G, Colombo N, et al.: Adjuvant therapy in early ovarian cancer. Proc Soc Gynecol Oncol 1994, A14.

  14. McGuire WP, Hoskins WJ, Brady MF, et al.: Cyclophosphamide and cisplatin compared with paclitaxel and cisplatin in patients with stage III and stage IV ovarian cancer. N Engl J Med 1996, 334:1–6.

    Article  PubMed  CAS  Google Scholar 

  15. Piccart MJ, Bertelsen K, James K, et al.: Randomized intergroup trial of cisplatin-paclitaxel v. cisplatincyclophosphamide in women with advanced epithelial ovarian cancer: three-year results. J Natl Cancer Inst 2000, 92:699–708.

    Article  PubMed  CAS  Google Scholar 

  16. Neijt JP, Engelholm SA, Tuxen MK, et al.: Exploratory Phase III study of paclitaxel and cisplatin versus paclitaxel and carboplatin in advanced ovarian cancer. J Clin Oncol 2000, 18:3084–3092.

    PubMed  CAS  Google Scholar 

  17. Ozols RF, Bundy BN, Fowler J, et al.: Randomized Phase III study of cisplatin(CIS)/paclitaxel(PAC) versus carboplatin/PAC in optimal stage III epithelial ovarian cancer (OC): a Gynecologic Oncology Group trial (GOG 158). Proc Am Soc Clin Oncol 1999, 18:356a.

    Google Scholar 

  18. duBois A, Lueck HJ, Meier W, et al.: Cisplatin/paclitaxel vs carboplatin/paclitaxel in ovarian cancer: update of an Arbeitgemeinschaft Gynaekologische Onkologie (AGO) study group trial. Proc Am Soc Clin Oncol 1999, 18:356a.

    Google Scholar 

  19. duBois A, Neijt JP, Thigpen JT: First-line chemotherapy the carboplatin plus paclitaxel in advanced ovarian cancer—a new standard of care? Ann Oncol 1999, 10:35–41.

    Article  Google Scholar 

  20. Ozols RF: Paclitaxel (Taxol)/carboplatin combination chemotherapy in the treatment of advanced ovarian cancer. Semin Oncol 2000, 27:3–7.

    PubMed  CAS  Google Scholar 

  21. Weiss RB, Donehower RC, Wiernik PH, et al.: Hypersensitivity reactions from Taxol. J Clin Oncol 1990, 8:1263–1268.

    PubMed  CAS  Google Scholar 

  22. Eisenhauer EA, ten Bokkel Huinink WW, Swenerton KD, et al.: European-Canadian randomized trial of paclitaxel in relapsed ovarian cancer. High-dose versus low-dose and long versus short infusion. J Clin Oncol 1994, 12:2654–2666.

    PubMed  CAS  Google Scholar 

  23. Markman M, Kennedy A, Webster K, et al.: Paclitaxelassociated hypersensitivity reactions: experience of the Gynecologic Oncology Program of the Cleveland Clinic Cancer Center. J Clin Oncol 2000, 18:102–105.

    PubMed  CAS  Google Scholar 

  24. Peereboom DM, Donehower RC, Eisenhauer EA, et al.: Successful re-treatment with Taxol after major hypersensitivity reactions. J Clin Oncol 1993, 11:885–890.

    PubMed  CAS  Google Scholar 

  25. Egorin MJ, vanEcho DA, Tipping SJ, et al.: Pharmacokinetics and dosage reduction of cis-diammine (1,1-cyclburanedicarboxylato)-platinum in patients with impaired renal function. Cancer Res 1984, 44:5432–5438.

    PubMed  CAS  Google Scholar 

  26. Calvert AH, Newell DR, Gumbrell LA, et al.: Carboplatin dosage: prospective evaluation of a simple formula based on renal function. J Clin Oncol 1989, 7:1748–1756.

    PubMed  CAS  Google Scholar 

  27. Markman M, Kennedy A, Webster K, et al.: Clinical features of hypersensitivity reactions to carboplatin. J Clin Oncol 1999, 17:1141–1145.

    PubMed  CAS  Google Scholar 

  28. Kintzel PE, Dorr RO: Anticancer drug renal toxicity and elimination. Dosing guidelines for altered renal function. Cancer Treat Rev 1995, 21:33–64.

    Article  PubMed  CAS  Google Scholar 

  29. Marty M, Pouillart P, Scholl S, et al.: Comparison of the 5-hydroxytryptamine 3 (serotonin) antagonist ondansetron (GR38032F) with high-dose metoclopramide in control of cisplatin-induced emesis. N Engl J Med 1990, 322:846–848.

    Article  Google Scholar 

  30. Morrow GR, Hickok JT, Rosenthal SN: Progress I reducing nausea and emesis. Comparisons of ondansetron (Zofran), granisetron (Kytril), and tropisetron (Navoban). Cancer 1995, 76:343–357.

    Article  PubMed  CAS  Google Scholar 

  31. Markman M, Rothman R, Hakes T, et al.: Second-line platinum therapy in patients with ovarian cancer previously treated with cisplatin. J Clin Oncol 1991, 9:389–393.

    PubMed  CAS  Google Scholar 

  32. Rose PG, Fusco N, Fluellen L, Rodriguez M: Second-line therapy with paclitaxel and carboplatin for recurrent disease following first-line therapy with paclitaxel and platinum ovarian or peritoneal carcinoma. J Clin Oncol 1998, 16:1494–1497.

    PubMed  CAS  Google Scholar 

  33. Thigpen JT, Blessing JA, Ball H, et al.: Phase II trial of paclitaxel in patients with progressive ovarian carcinoma after platinum based chemotherapy: a Gynecologic Oncology Group study. J Clin Oncol 1994, 12:1748–1753.

    PubMed  CAS  Google Scholar 

  34. Zannotti KM, Belinson JL, Kennedy AW, et al.: Treatment of relapsed carcinoma of the ovary with singleagent paclitaxel following exposure to paclitaxel and platinum employed as initial therapy. Gynecol Oncol 2000, 79:211–215.

    Article  CAS  Google Scholar 

  35. Abu-Rustum NR, Aghajanian C, Barakat R, et al.: Salvage weekly paclitaxel in recurrent ovarian cancer. Semin Oncol 1997, 24:s62-s67.

    CAS  Google Scholar 

  36. McGuire WP, Blessing JA, Bookman MA, et al.: Topotecan has substantial antitumor activity as first-line salvage therapy in platinum-sensitive epithelial ovarian carcinoma: a Gynecologic Oncology Group study. J Clin Oncol 2000, 18:1062–1067.

    PubMed  CAS  Google Scholar 

  37. Rose PG, Blessing JA, Mayer AR, et al.: Prolonged oral etoposide as second-line therapy for platinumresistant and platinum-sensitive ovarian carcinoma. A Gynecologic Oncology Group study. J Clin Oncol 1998, 16:405–410.

    PubMed  CAS  Google Scholar 

  38. Creemers GJ, Bolis G, Gore M, et al.: Topotecan, an active drug in the second-line treatment of epithelial ovarian cancer: results of a large European Phase II trial. J Clin Oncol 1996, 14:3056–3061.

    PubMed  CAS  Google Scholar 

  39. Kudelka AP, Tresukosol D, Edwards CL, et al.: Phase II study of intravenous topotecan as a 5 day infusion for refractory epithelial ovarian carcinoma. J Clin Oncol 1996, 14:1552–1557.

    PubMed  CAS  Google Scholar 

  40. ten Bokkel Huinink WW, Gore M, Carmichael J, et al.: Topotecan versus paclitaxel for the treatment of recurrent epithelial ovarian cancer. J Clin Oncol 1997, 15:2183–2193.

    Google Scholar 

  41. Bookman MA, Malmstrom H, Bolis G, et al.: Topotecan for the treatment of advanced epithelial ovarian cancer: an open-label Phase II study in patients treated after prior chemotherapy containing cisplatin or carboplatin and paclitaxel. J Clin Oncol 1998, 16:3345–3352.

    PubMed  CAS  Google Scholar 

  42. Muggia FM, Hainsworth JD, Jeffers S, et al.: Phase II study of liposomal doxorubicin in refractory ovarian cancer: antitumor activity and toxicity modification by liposomal encapsulation. J Clin Oncol 1997, 15:987–993.

    PubMed  CAS  Google Scholar 

  43. Gordon AN, Granai CO, Rose PG, et al.: Phase II study of liposomal doxorubicin in platinum- and paclitaxelrefractory epithelial ovarian cancer. J Clin Oncol 2000, 18:3093–3100.

    PubMed  CAS  Google Scholar 

  44. Markman M, Kennedy A, Webster K, et al.: Phase 2 trial of liposomal doxorubicin (40 mg/m2) in platinum/ paclitaxel-refractory ovarian and fallopian tube cancers and primary carcinoma of the peritoneum. Gynecol Oncol 2000, 78:369–372.

    Article  PubMed  CAS  Google Scholar 

  45. Shapiro JD, Millward MJ, Rischin D, et al.: Activity of gemcitabine in patients with advanced ovarian cancer: responses seen following platinum and paclitaxel. Gynecol Oncol 1996, 63:89–93.

    Article  PubMed  CAS  Google Scholar 

  46. Bajetta E, Di Leo A, Biganzoli L, et al.: Phase II study of vinorelbine in patients with pretreated advanced ovarian cancer: activity in platinum-resistant disease. J Clin Oncol 1996, 14:2546–2551.

    PubMed  CAS  Google Scholar 

  47. Burger RA, Di Saia PJ, Roberts JA, et al.: Phase II trial of vinorelbine in recurrent and progressive epithelial ovarian cancer. Gynecol Oncol 1999, 72:148–153.

    Article  PubMed  CAS  Google Scholar 

  48. Francis P, Schneider J, Hann L, et al.: Phase II trial of docetaxel in patients with platinum-refractory advanced ovarian cancer. J Clin Oncol 1994, 12:2301–2308.

    PubMed  CAS  Google Scholar 

  49. Piccart MJ, Gore M, ten Bokkel Huinink WW, et al.: Docetaxel: an active new drug for treatment of advanced epithelial ovarian cancer. J Natl Cancer Inst 1995, 87:676–681.

    Article  PubMed  CAS  Google Scholar 

  50. Verschraegen CF, Sittisomwong T, Kudelka AP, et al.: Docetaxel for patients with paclitaxel-resistant Mullerian carcinoma. J Clin Oncol 2000, 18:2733–2739.

    PubMed  CAS  Google Scholar 

  51. Fennelly D, Aghajanian C, Shapiro F, et al.: Phase I and pharmacologic study of paclitaxel administered weekly in patients with relapsed ovarian cancer. J Clin Oncol 1997, 15:187–192.

    PubMed  CAS  Google Scholar 

  52. Sutton GP, Blessing JM, Homesley HD, et al.: Phase II trial of ifosfamide and mesna in advanced ovarian carcinoma: a Gynecologic Oncology Group study. Gynecol Oncol 1989, 7:1672–1676.

    CAS  Google Scholar 

  53. Sorenson P, Pfeiffer P, Bertelsen K: A Phase 2 trial of ifosfamide/mesna as salvage therapy in patients with ovarian cancer refractory to or relapsing after prior platinum-containing chemotherapy. Gynecol Oncol 1995, 56:75–78.

    Article  Google Scholar 

  54. Markman M, Hakes T, Reichman B, et al.: Ifosfamide and mesna in previously treated advanced epithelial ovarian cancer: activity in platinum-resistant disease. J Clin Oncol 1992, 10:243–248.

    PubMed  CAS  Google Scholar 

  55. Markman M, Kennedy A, Sutton G, et al.: Phase 2 trial of single agent ifosfamide/mesna in patients with platinum/paclitaxel refractory ovarian cancer who have not previously been treated with an alkylating agent. Gynecol Oncol 1998, 70:272–274.

    Article  PubMed  CAS  Google Scholar 

  56. Hatch KD, Beecham JB, Blessing JA, et al.: Responsiveness of patients with advanced ovarian carcinoma to tamoxifen. A Gynecologic Oncology Group study of second-line therapy in 105 patients. Cancer 1991, 68:269–271.

    Article  PubMed  CAS  Google Scholar 

  57. Ahlgren JD, Ellison NM, Gottliev RJ, et al.: Hormonal palliation of chemoresistant ovarian cancer: three consecutive Phase II trials of the Mid-Atlantic Oncology Program. J Clin Oncol 1993, 11:1957–1968.

    PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Memorial Sloan-Kettering Cancer Center, 1275 York Avenue, 10021, New York, NY, USA

    Martee L. Hensley MD,MSc

Authors
  1. Martee L. Hensley MD,MSc
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Cite this article

Hensley, M.L. Epithelial ovarian cancer. Curr. Treat. Options in Oncol. 3, 131–141 (2002). https://doi.org/10.1007/s11864-002-0059-3

Download citation

  • Issue Date:

  • DOI: https://doi.org/10.1007/s11864-002-0059-3

Keywords

Search

Navigation